Details for Patent: 8,771,648

Which drugs does patent 8,771,648 protect, and when does it expire?

Patent 8,771,648 protects TAVALISSE and is included in one NDA.

This patent has thirty-one patent family members in twenty-five countries.

Summary for Patent: 8,771,648

Patent landscape, scope, and claims:

Title:	(Trimethoxyphenylamino) pyrimidinyl formulations
Abstract:	There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them. ##STR00001##
Inventor(s):	Gururajan; Bindhumadhavan (Molndal, SE), Alhusban; Farhan Abdul Karim (Macclesfield, GB), Gabbott; Ian Paul (Macclesfield, GB), Simpson; David Bradley Brook (Macclesfield, GB), Sievwright; Dawn (Macclesfield, GB)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	13/559,805
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,771,648

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-001	Apr 17, 2018		RX	Yes	No	8,771,648		Y
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018		RX	Yes	Yes	8,771,648		Y

International Family Members for US Patent 8,771,648

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	087371
Australia	2012288632
Brazil	112014001999
Canada	2843138
China	103826610